



US0D1089256S

(12) **United States Design Patent** (10) **Patent No.:** **US D1,089,256 S**
Morgan et al. (45) **Date of Patent:** **** Aug. 19, 2025**

(54) **DISPLAY SCREEN OR PORTION THEREOF WITH A GRAPHICAL USER INTERFACE**

(57) **CLAIM**

The ornamental design for a display screen or portion thereof with a graphical user interface, as shown and described.

(71) Applicant: **DecisionRx, Inc.**, Dover, DE (US)

(72) Inventors: **Travis Allen Morgan**, Dover, DE (US);
Hazem Fathy Elewa, Dover, DE (US);
Bradley Allen Bostic, Dover, DE (US)

(73) Assignee: **DECISIONRX, INC.**, Dover, DE (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/923,560**

(22) Filed: **Dec. 29, 2023**

(51) **LOC (15) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/485**

(58) **Field of Classification Search**

USPC D14/485-488
CPC G06F 3/048; G06F 3/0481; G06F 3/04817;
G06F 3/0482; G06F 3/0483; G06F
3/04842; G06F 3/0485; G06F 3/04855;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

D737,840 S * 9/2015 Omiya D14/486
D748,126 S * 1/2016 Sarukkai D14/486
(Continued)

OTHER PUBLICATIONS

MTO Platform, posted unknown [online], [retrieved May 30, 2025].
Retrieved from internet, <https://decisionrx.com/about/payors-providers/mto-platform/> (Year: 2025).*

Primary Examiner — Christian P. McLean

Assistant Examiner — Alisha K Miles

(74) Attorney, Agent, or Firm — RMCK Law Group,
PLC

DESCRIPTION

FIG. 1 is a front view of a first embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 2 is a front view of a second embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 3 is a front view of a third embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 4 is a front view of a fourth embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 5 is a front view of a fifth embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 6 is a front view of a sixth embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 7 is a front view of a seventh embodiment of a display screen or portion thereof with a graphical user interface showing our new design;


FIG. 8 is a front view of an eighth embodiment of a display screen or portion thereof with a graphical user interface showing our new design;

FIG. 9 is a front view of a ninth embodiment of a display screen or portion thereof with a graphical user interface showing our new design; and,

FIG. 10 is a front view of a tenth embodiment of a display screen or portion thereof with a graphical user interface showing our new design.

The broken lines show portions of the display screen or portion thereof with a graphical user interface that form no part of the claimed design.

1 Claim, 10 Drawing Sheets



(58) **Field of Classification Search**

CPC .. G06F 3/0486; G06F 3/0488; G06F 3/04886;
 G06F 9/451; G06F 40/103; G06F 40/106;
 G06F 40/189; G06F 40/191; G16H 20/00;
 G16H 20/10; G16H 70/00; G16H 70/40;
 G16H 10/60; G16H 10/40; G16H 50/30;
 G16H 15/00

See application file for complete search history.


(56) **References Cited**

U.S. PATENT DOCUMENTS

D780,203	S *	2/2017	Bray	D14/493
D788,800	S *	6/2017	Wu	D14/486
D789,387	S *	6/2017	Reyes	D14/485
D814,490	S *	4/2018	Bell	D14/486
D830,402	S *	10/2018	Javed	D14/486
D840,421	S *	2/2019	Chalker	D14/485
D864,232	S *	10/2019	Lu	D14/486
D873,289	S *	1/2020	Roche, Jr.	D14/486
D882,597	S *	4/2020	Yamazaki	D14/485
D890,793	S *	7/2020	Loper	D14/487
D891,451	S *	7/2020	Pontious	D14/486
D910,696	S *	2/2021	Lee	D14/487
D942,481	S *	2/2022	Waissman	D14/486
D975,120	S *	1/2023	Barnard	D14/486
D980,266	S *	3/2023	Chan	D14/488
D980,267	S *	3/2023	Chan	D14/488
D1,045,890	S *	10/2024	Kim	D14/485
D1,053,897	S *	12/2024	Sumarsono	D14/488
2011/0184756	A1 *	7/2011	Yamaga	G06Q 10/00 705/3

* cited by examiner

FIG. 5



Patient : Jim Smith DOB: April 3, 1970
 Patient ID : PRxTest-753641 Report Date: 2023-06-17

Summary of Proposed Medication Changes

⊖ Discontinue	⊕ Initiate	⊙ Modify	📊 Monitor
Codaine	→ oxycodone HCl	⊙	📊
Plavix	→ Brilinta		📊
Verapamil HCl ER	Potassium Chloride ER		

Current Medication Regimen

										RISK	
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
30	30	30	40	40	50	0	0	0		0	100

Codaine 30 MG
1 Tablet, Three Times Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
30	30	30	40	40	50	0	0	0		30	100

Eligade 5 MG
1 Tablet, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
5	5	5	10	10	15	0	0	0		5	15

Lasix 40 MG
1 Tablet, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
40	40	40	50	50	60	0	0	0		40	60

Plavix 75 MG
1 Tablet, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
75	75	75	80	80	90	0	0	0		75	90

Verapamil HCl ER 180 MG
1 Tablet Extended Release, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
180	180	180	190	190	200	0	0	0		180	200

Proposed Medication Regimen

										RISK	
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
0	30	0	40	40	50	0	0	0		0	140

oxycodone HCl 5mg
1 Tablet, Twice daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
5	5	5	10	10	15	0	0	0		5	15

Eligade 5 MG
1 Tablet, Twice Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
5	5	5	10	10	15	0	0	0		5	15

Lasix 40 MG
1 Tablet, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
40	40	40	50	50	60	0	0	0		40	60

Plavix 75 MG
1 Tablet, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
75	75	75	80	80	90	0	0	0		75	90

Brilinta 90mg
1 Tablet, Twice Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
90	90	90	100	100	110	0	0	0		90	110


Potassium Chloride ER 10 MEq
1 Tablet Extended Release, Once Daily

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		PGX	TOTAL
10	10	10	110	110	120	0	0	0		10	120

Always consult your physician(s) before making changes to your medication regimen.

Jim Smith, Page 1 of 2

FIG. 6



DecisionRx
 Medication Action Proposal

Patient : Jim Smith DOB: April 3, 1970
 Patient ID : PRxTest-753641 Report Date: 2023-06-17

Summary of Proposed Medication Changes

⊖ Discontinue

Codaine →

Plavix →

Verapamil HCl ER

⊕ Initiate

oxybutaphone HCl

Brilinta

Potassium Chloride ER

⌚ Modify

Eligade

📋 Monitor

Eligade

Brilinta

Current Medication Regimen

										RISK	
POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT	POX	TOTAL	
20	20	20	40	40	30	0	0	0	20	100	

Codaine 30 MG
1 Tablet, Three Times Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Eligade 5 MG
1 Tablet, Once Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Lasix 40 MG
1 Tablet, Once Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Warfarin 5 MG
1 Tablet, Once Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Plavix 75 MG
1 Tablet, Once Daily

POX: TOTAL: 40

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Verapamil HCl ER 180 MG
1 Tablet Extended Release, Once Daily

POX: TOTAL: 40

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Proposed Medication Regimen

										RISK	
POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT	POX	TOTAL	
0	20	0	40	40	30	0	0	0	0	140	

oxybutaphone HCl 5mg
1 Tablet, Twice daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Eligade 5 MG
1 Tablet, Twice Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Lasix 40 MG
1 Tablet, Once Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Warfarin 5 MG
1 Tablet, Once Daily

POX: TOTAL: 10

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Brilinta 90mg
1 Tablet, Twice Daily

POX: TOTAL: 20

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

Potassium Chloride ER 10 MG
1 Tablet Extended Release, Once Daily

POX: TOTAL: 10

POX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
20	20	20	40	40	30	0	0	0

replace ⊕

modify ⌚

keep ⊕

keep ⊕

replace ⊕

discontinue ⊖

initiate ⊕

Monitor Closely

Monitor Closely


The current medication is to be discontinued in the proposed regimen.

A new medication is to be initiated in the proposed regimen.

Always consult your physician(s) before making changes to your medication regimen.

Jim Smith, Page 1 of 2

FIG. 7



Patient : Jim Smith DOB: April 3, 1970
 Patient ID : PRxTest-753641 Report Date: 2023-06-17

Summary of Proposed Medication Changes

⊖ Discontinue	⊕ Initiate	⊗ Modify	📊 Monitor
Codaine	→ oxycodone HCl	Eligula	Eligula
Plavix	→ Brilinta		Brilinta
Verapamil HCl ER	Potassium Chloride ER		

Current Medication Regimen

										RISK	
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		20	100
										PGX	TOTAL
20	30	20	40	40	30	0	0	0			
Codaine 30 MG 1 Tablet, Three Times Daily PGX RMA TOTAL 50											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Eligula 5 MG 1 Tablet, Once Daily PGX RMA TOTAL 30											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Lasix 40 MG 1 Tablet, Once Daily PGX RMA TOTAL 20											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Plavix 75 MG 1 Tablet, Once Daily PGX RMA TOTAL 40											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Verapamil HCl ER 180 MG 1 Tablet Extended Release, Once Daily PGX RMA TOTAL 30											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			

Proposed Medication Regimen

										RISK	
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT		0	140
										PGX	TOTAL
0	30	0	40	40	30	0	0	0			
oxycodone HCl 5mg 1 Tablet, Twice daily PGX RMA TOTAL 50											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Eligula 5 MG 1 Tablet, Twice Daily PGX RMA TOTAL 30											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Lasix 40 MG 1 Tablet, Once Daily PGX RMA TOTAL 20											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Plavix 75 MG 1 Tablet, Once Daily PGX RMA TOTAL 40											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
Brilinta 90mg 1 Tablet, Twice Daily PGX RMA TOTAL 30											
PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			

replace ⊕

modify ⊗

keep ⊕

keep ⊕

replace ⊕

discontinue ⊖

initiate ⊕

Eligula 5 MG
1 Tablet, Twice Daily
PGX RMA TOTAL 30
Monitor Closely

Eligula 5 MG
1 Tablet, Twice Daily
PGX RMA TOTAL 30
Monitor Closely

Brilinta 90mg
1 Tablet, Twice Daily
PGX RMA TOTAL 30
Monitor Closely

The current medication is to be discontinued in the proposed regimen.


Potassium Chloride ER 10 MEq
1 Tablet Extended Release,
Once Daily
PGX RMA TOTAL 30

A new medication is to be initiated in the proposed regimen.

Always consult your physician(s) before making changes to your medication regimen.

Jim Smith, Page 1 of 2

FIG. 8



DecisionRx

Medication Action Proposal

Patient : Jim Smith DOB: April 3, 1970
 Patient ID : PRXTest-753641 Report Date: 2023-06-17

Summary of Proposed Medication Changes

⊖ Discontinue

~~Codaine~~

~~Plavix~~

~~Verapamil HCl ER~~

⊕ Initiate

oxycodone HCl

Brilinta

Potassium Chloride ER

⌚ Modify

~~Eligade~~

📊 Monitor

~~Eligade~~

Brilinta

Current Medication Regimen

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT	RISK
									PGX TOTAL
20	35	20	45	40	35	0	0	0	100

~~Codaine 30 MG~~
 1 Tablet, Three Times Daily
 PGX RISK TOTAL 20 100

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

~~Eligade 5 MG~~
 1 Tablet, Once Daily
 PGX RISK TOTAL 35 100

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

~~Lasix 40 MG~~
 1 Tablet, Once Daily
 PGX RISK TOTAL 20 100

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

~~Rivaroxan 5 MG~~
 1 Tablet, Once Daily
 PGX RISK TOTAL 35 100

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

~~Plavix 75 MG~~
 1 Tablet, Once Daily
 PGX RISK TOTAL 40 100

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

~~Verapamil HCl ER 180 MG~~
 1 Tablet Extended Release, Once Daily
 PGX RISK TOTAL 35 100

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

Proposed Medication Regimen

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT	RISK
									PGX TOTAL
0	30	0	40	40	30	0	0	0	140

oxycodone HCl 5mg
 1 Tablet, Twice daily
 PGX RISK TOTAL 30 140

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

Eligade 5 MG
 1 Tablet, Twice Daily
 PGX RISK TOTAL 30 140
📊 Monitor Closely

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

Lasix 40 MG
 1 Tablet, Once Daily
 PGX RISK TOTAL 30 140

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

Rivaroxan 5 MG
 1 Tablet, Once Daily
 PGX RISK TOTAL 30 140

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

Brilinta 90mg
 1 Tablet, Twice Daily
 PGX RISK TOTAL 30 140
📊 Monitor Closely

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

The current medication is to be discontinued in the proposed regimen.

A new medication is to be initiated in the proposed regimen.


Potassium Chloride ER 10 MG
 1 Tablet Extended Release, Once Daily
 PGX RISK TOTAL 30 140

PGX	DDI	TD	CI	BB	AE	DLI	AGE	MAT

Always consult your physician(s) before making changes to your medication regimen.

Jim Smith, Page 1 of 2

FIG. 9



DecisionRx

Medication Action Proposal

Patient : Jim Smith DOB: April 3, 1970
 Patient ID : PRxTest-753641 Report Date: 2023-06-17

Summary of Proposed Medication Changes

⊖ Discontinue

Codaine →

Plavix →

Verapamil HCl ER

⊕ Initiate

oxycodone HCl

Brilinta

Potassium Chloride ER

⊗ Modify

Eligade

📋 Monitor

Eligade

Brilinta

Current Medication Regimen

										RISK	
										20	100
										PCX	TOTAL
PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
30	30	30	40	40	50	0	0	0			

Codaine 30 MG
 1 Tablet, Three Times Daily
 PCX: 30 TOTAL: 30

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
30	30	30	40	40	50	0	0	0

Eligade 5 MG
 1 Tablet, Once Daily
 PCX: 50 TOTAL: 50

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
50	50	50	60	60	70	0	0	0

Lasix 40 MG
 1 Tablet, Once Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Warfarin 5 MG
 1 Tablet, Once Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Plavix 75 MG
 1 Tablet, Once Daily
 PCX: 50 TOTAL: 50

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
50	50	50	60	60	70	0	0	0

Verapamil HCl ER 180 MG
 1 Tablet Extended Release, Once Daily
 PCX: 50 TOTAL: 50

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
50	50	50	60	60	70	0	0	0

Proposed Medication Regimen

										RISK	
										0	140
										PCX	TOTAL
PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT			
0	30	0	40	40	50	0	0	0			

oxycodone HCl 5mg
 1 Tablet, Twice daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Eligade 5 MG
 1 Tablet, Twice Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Lasix 40 MG
 1 Tablet, Once Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Warfarin 5 MG
 1 Tablet, Once Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Brilinta 90mg
 1 Tablet, Twice Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

Potassium Chloride ER 10 MG
 1 Tablet Extended Release, Once Daily
 PCX: 100 TOTAL: 100

PCX	DDI	TD	CI	BB	AE	DLI	AGE	MAT
100	100	100	110	110	120	0	0	0

replace ⊕

modify ⊗

keep ⊕

keep ⊕

replace ⊕

discontinue ⊖

initiate ⊕

The current medication is to be discontinued in the proposed regimen.

A new medication is to be initiated in the proposed regimen.

Always consult your physician(s) before making changes to your medication regimen.

Jim Smith, Page 1 of 2

FIG. 10